MUC16 and cancer: Amatuximab (MORAb-009), a monoclonal anti-ERC/mesothelin antibody, inhibits the interaction of ERC/mesothelin with CA125/MUC16 [14,15,16] and reduces the cancer’s ability to invade other tissues.